FDA 483 - Genicon, Inc. - January 17, 2020

Genicon, Inc. received a Form 483 citing 15 observations related to significant deficiencies in its quality system for medical devices. Issues include inadequate organizational structure, complaint handling, purchasing controls, MDR reporting, CAPA, design controls, and sterilization validation. These deficiencies indicate a systemic breakdown in ensuring device safety and efficacy.